MTOR and cancer: Metformin mediates mammalian target of rapamycin (mTOR) pathway via the activation of AMPK and tuberous sclerosis complex 2 (TSC2), phosphorylation of TSC2 which leads to an inhibition of mTOR signaling and reduction in protein synthesis for cancer cells.